Azienda Sanitaria dell'Alto Adige   Report issue

Government Phase 2 Phase 3 Phase 4
Founded: Merano Italy (2007)

Organization Overview

First Clinical Trial
2013
NCT02076594
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

ASDAA Bolzano, Oncologia Medica | ASP di Bolzano - Comprensorio sanitario di Bolzano | Azienda Sanitaria dell'Alto Adige

Active Ingredients

Drugs in Phase 4 Trials (1)

fentanyl (Innovar) (2 trials)

Drugs in Phase 3 Trials (4)

capecitabine (xeloda) (1 trial)

docetaxel (taxotere) (1 trial)

epirubicin (ellence) (1 trial)

oxaliplatin (eloxatin) (1 trial)

Drugs in Phase 2 Trials (1)

vinorelbine (navelbine) (1 trial)

Drugs in Other Trials (2)

ketamine (ketalar) (1 trial)

midazolam (versed) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Pain (Phase 4)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Lung Neoplasms (Phase 2)

Stomach Neoplasms (Phase 3)

Wounds and Injuries (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 8